Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Labetuzumab I-131

Next Previous
X
Search
Drug Profile

Labetuzumab I-131

Alternative Names: Anti-CEA monoclonal antibody MN 14-I-131; CEA-Cide-I-131; hAFP-Y-90; Humanised anti-CEA monoclonal antibody MN 14-I-131; IMMU-111

Latest Information Update: 15 Apr 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals; Radiosensitisers
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Liver cancer; Thyroid cancer

Most Recent Events

  • 15 Apr 2021 Discontinued - Phase-II for Colorectal cancer in Germany (IV)
  • 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
  • 03 Jun 2008 Efficacy and adverse events data from a phase II trial in colorectal liver metastases presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top